iTeos Therapeutics Reports Major Corporate Changes
| Field | Detail |
|---|---|
| Company | Iteos Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | high |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.001, $10.047 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, delisting, corporate-governance, change-of-control
TL;DR
iTeos Therapeutics is undergoing major changes: acquisition/disposition, potential delisting, control changes, and executive shifts.
AI Summary
On August 29, 2025, iTeos Therapeutics, Inc. filed an 8-K report detailing several significant events. These include the completion of an acquisition or disposition of assets, a notice of delisting or failure to meet listing standards, material modifications to security holder rights, and changes in control of the registrant. The filing also addresses departures of directors or officers, amendments to articles of incorporation, and financial statements.
Why It Matters
This 8-K filing indicates substantial shifts in iTeos Therapeutics' corporate structure and listing status, which could significantly impact its operations, governance, and stock market presence.
Risk Assessment
Risk Level: high — The filing mentions potential delisting and changes in control, which are significant risk factors for investors.
Key Players & Entities
- iTeos Therapeutics, Inc. (company) — Registrant
- August 29, 2025 (date) — Date of earliest event reported
FAQ
What specific assets were acquired or disposed of by iTeos Therapeutics?
The filing indicates the completion of an acquisition or disposition of assets, but does not specify the assets involved.
What is the reason for the notice of delisting or failure to satisfy a continued listing rule?
The filing acknowledges a notice of delisting or failure to satisfy a continued listing rule, but the specific reasons are not detailed in this summary.
What material modifications have been made to the rights of security holders?
The report states there have been material modifications to the rights of security holders, but the nature of these modifications is not specified.
What changes in control of iTeos Therapeutics, Inc. have occurred?
The filing reports changes in control of the registrant, but the details of these changes are not provided in the summary.
Are there any departures of directors or certain officers mentioned in the filing?
Yes, the filing indicates departures of directors or certain officers, along with the election of directors and appointment of officers, and compensatory arrangements.
Filing Stats: 2,197 words · 9 min read · ~7 pages · Grade level 13.3 · Accepted 2025-08-29 09:00:37
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ITOS The Nasdaq
- $10.047 — nd each a "Share"), in exchange for (i) $10.047 in cash per Share (the "Cash Amount");
Filing Documents
- d938711d8k.htm (8-K) — 42KB
- d938711dex22.htm (EX-2.2) — 121KB
- d938711dex31.htm (EX-3.1) — 7KB
- d938711dex32.htm (EX-3.2) — 92KB
- 0001193125-25-192031.txt ( ) — 445KB
- itos-20250829.xsd (EX-101.SCH) — 3KB
- itos-20250829_lab.xml (EX-101.LAB) — 18KB
- itos-20250829_pre.xml (EX-101.PRE) — 11KB
- d938711d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits No. Description of Exhibit 2.1+ Agreement and Plan of Merger, dated as of July 18, 2025, by and among iTeos Therapeutics, Inc., Concentra Biosciences, LLC, and Concentra Merger Sub VIII, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on July 21, 2025). 2.2+ Contingent Value Rights Agreement, dated August 29, 2025, by and among Concentra Biosciences, LLC, Concentra Merger Sub VIII, Inc., Broadridge Corporate Issuer Solutions, LLC and Fortis Advisors LLC. 3.1 Amended and Restated Certificate of Incorporation of iTeos Therapeutics, Inc. 3.2 Amended and Restated Bylaws of iTeos Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). + Certain schedules and annexes have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules and annexes upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any annexes or schedules so furnished.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. iTeos Therapeutics, Inc. Date: August 29, 2025 By: /s/ Michel Detheux, Ph.D. Michel Detheux, Ph.D. President and Chief Executive Officer